Physician profile
Karla E Luker
NPI 1376553719
$3,184.04
in general payments reported to CMS, 2019-2025
30 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $994 · 2022: $1,216 · 2023: $953 · 2024: $20.89.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $974.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $973.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $725.44 | 2021-2023 | |
| Amgen INC. | $424.18 | 2021-2023 | Tavneos, Enbrel, Prolia |
| Mallinckrodt Hospital Products INC. | $311.27 | 2021-2023 | Acthar |
| Lilly USA, LLC | $257.18 | 2021-2023 | Taltz |
| Novartis Pharmaceuticals Corporation | $224.79 | 2021-2023 | |
| E.R. Squibb & Sons, L.L.C. | $191.89 | 2021-2023 | Orencia |
| Ucb, INC. | $173.78 | 2021-2023 | Cimzia |
| Janssen Biotech, INC. | $156.70 | 2021-2023 | Tremfya |
| Astrazeneca Pharmaceuticals LP | $94.85 | 2021-2023 | Saphnelo, Evusheld |
| Pfizer INC. | $82.06 | 2022-2023 | |
| Tg Therapeutics, INC. | $77.23 | 2023-2024 | |
| Glaxosmithkline, LLC. | $72.08 | 2021-2023 | Benlysta |
| Genzyme Corporation | $41.13 | 2021 | |
| Horizon Therapeutics Plc | $31.87 | 2022-2023 | Krystexxa |
| Allergan, INC. | $29.71 | 2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $25.39 | 2021 | |
| Amryt Pharma Holdings LTD | $24.63 | 2023 | Mycapssa |
| Genentech USA, INC. | $24.33 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $22.86 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $21.88 | 2022 | |
| Sobi, INC | $21.02 | 2021 | |
| Xeris Pharmaceuticals, INC. | $20.81 | 2021 | |
| Scilex Pharmaceuticals INC. | $20.21 | 2023 | Ztlido |
| Novo Nordisk INC | $18.84 | 2021 | |
| Amneal Pharmaceuticals LLC | $16.81 | 2022 | |
| Ascensia Diabetes Care US INC. | $16.67 | 2023 | |
| Janssen Pharmaceuticals, INC | $16.28 | 2022 | |
| Esperion Therapeutics, INC. | $14.41 | 2023 | Nexletol |
| Alexion Pharmaceuticals, INC. | $14.33 | 2023 | Strensiq |
| Merck Sharp & Dohme LLC | $11.41 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karla Luker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.